Tiny cancer study halted after just one patient
NCT ID NCT06338657
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial aimed to see how a new version of the chemotherapy drug paclitaxel, called FID-007, affects immune cells in head and neck cancer tumors. Researchers planned to study tumor samples before and after treatment in people scheduled for surgery. However, the study was terminated after enrolling only one participant, so no meaningful results were obtained.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- FID-007 (a polymer-encapsulated form of paclitaxel)
- What this could lead to
- If successful, this could point toward better ways to use chemotherapy to boost the immune system's attack on head and neck cancers.
- What could go wrong
- This was a very early, tiny trial that was terminated after just one participant. It is far too small to draw any conclusions, and the drug may not work or may cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Los Angeles General Medical Center
Los Angeles, California, 90033, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital peer support: a new weapon against cancer treatment anxiety?
- Can targeted radiation boost Immunotherapy's power against head and neck cancer?
- Could a simple mouthwash protect cancer patients from Radiation's painful side effects?
- Can a scan tell who needs more surgery after head and neck cancer?
- Can a new drug outperform standard care for head and neck cancer?
- Exercise after cancer therapy: a new way to gauge prognosis?